Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
190.35
+7.75 (4.24%)
Aug 7, 2025, 4:00 PM - Market closed
Paycor HCM Employees
Ascendis Pharma had 1,017 employees as of December 31, 2024. The number of employees increased by 138 or 15.70% compared to the previous year.
Employees
1,017
Change (1Y)
138
Growth (1Y)
15.70%
Revenue / Employee
$566,698
Profits / Employee
-$313,116
Market Cap
11.53B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,017 | 138 | 15.70% |
Dec 31, 2023 | 879 | 82 | 10.29% |
Dec 31, 2022 | 797 | 158 | 24.73% |
Dec 31, 2021 | 639 | 157 | 32.57% |
Dec 31, 2020 | 482 | 152 | 46.06% |
Dec 31, 2019 | 330 | 114 | 52.78% |
Dec 31, 2018 | 216 | 79 | 57.66% |
Dec 31, 2017 | 137 | 36 | 35.64% |
Dec 31, 2016 | 101 | 23 | 29.49% |
Dec 31, 2015 | 78 | 23 | 41.82% |
Dec 31, 2014 | 55 | 10 | 22.22% |
Dec 31, 2013 | 45 | 7 | 18.42% |
Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ASND News
- 13 hours ago - Ascendis Pharma Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 7 days ago - Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 - GlobeNewsWire
- 10 days ago - FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency - GlobeNewsWire
- 24 days ago - New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life - GlobeNewsWire
- 4 weeks ago - Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025 - GlobeNewsWire
- 2 months ago - TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial - GlobeNewsWire
- 2 months ago - FDA Accepts TransCon® CNP NDA for Priority Review - GlobeNewsWire
- 2 months ago - Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction - Accesswire